Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phas... by Waddell, Tom, MBBCh, Chau, Ian, MD, Cunningham, David, Prof, Gonzalez, David, PhD, Okines, Alicia Frances Clare, MBBCh, Wotherspoon, Andrew, MBBCh, Saffery, Claire, Middleton, Gary, MD, Wadsley, Jonathan, MBBCh, Ferry, David, Prof, Mansoor, Wasat, PhD, Crosby, Tom, MBBS, Coxon, Fareeda, MBBS, Smith, David, MD, Waters, Justin, PhD, Iveson, Timothy, MD, Falk, Stephen, MD, Slater, Sarah, MD, Peckitt, Clare, MSc, Barbachano, Yolanda, PhD

Get full text

Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial by Chua, Yu Jo, FRACP, Barbachano, Yolanda, PhD, Cunningham, David, Prof, Oates, Jacqui R, Brown, Gina, MD, Wotherspoon, Andrew, MRCPath, Tait, Diana, MD, Massey, Alison, Dip Onc, Tebbutt, Niall C, PhD, Chau, Ian, MD

Get full text